A 60-year-old woman with mild memory impairment: Review of mild cognitive impairment

JAMA

Volumn 300, Issue 13, 2008, Pages 1566-1574

  Ellison, James M ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Geriatric Psychiatry Program

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTIOXIDANT; APOLIPOPROTEIN E; ATORVASTATIN; CITALOPRAM; DOCOSAHEXAENOIC ACID; DONEPEZIL; ESTROGEN; FLUOXETINE; FOLIC ACID; GALANTAMINE; GESTAGEN; GINKGO BILOBA EXTRACT; ICOSAPENTAENOIC ACID; MEMANTINE; PAROXETINE; PLACEBO; RIVASTIGMINE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; ANAMNESIS; ANXIETY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIETARY INTAKE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EXERCISE; FATIGUE; GERIATRIC DEPRESSION SCALE; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; LEARNING TEST; LIFESTYLE MODIFICATION; MEMORY DISORDER; MENTAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECALL; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; AGING; ARTICLE; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; COGNITION; COUNSELING; DIAGNOSIS; DIET; DIFFERENTIAL DIAGNOSIS; FEMALE; LIFESTYLE; MIDDLE AGED; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR;

AGING; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; COUNSELING; DIAGNOSIS, DIFFERENTIAL; DIET; FEMALE; HUMANS; LIFE STYLE; MAGNETIC RESONANCE IMAGING; MEMORY DISORDERS; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PAROXETINE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 54849160200     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.9.jrr80008     Document Type: Review

References (89)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
2. Nilsson L-G. Memory function in normal aging. Acta Neurol Scand. 2003;107(1)(suppl 179):7-13.
3. Green J. Neuropsychological Evaluation of the Older Adult: A Clinician's Guidebook. San Diego, CA: Academic Press; 2000.
4. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003;2(1):15-21.
5. Jonker C, Geerlings M, Schmand B. Are memory complaints predictive for dementia? a review of clinical and population-based studies. Int J Geriatr Psychiatry. 2000;15(11):983-991.
6. Jessen F, Wiese B, Cvetanovska G, et al. Patterns of subjective memory impairment in the elderly: association with memory performance. Psychol Med. 2007;37(12):1753-1762.
7. Tsai DH, Green R, Benke K, et al. Predictors of subjective memory complaint in cognitively normal relatives of patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2006;18(3):384-388.
8. Reid LM, MacLullich A. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord. 2006;22(5-6):471-485.
9. Weiner DK, Rudy T, Morrow L, et al. The relationship between pain, neuropsychological performance, and physical function in community-dwelling older adults with chronic low back pain. Pain Med. 2006;7(1):60-70.
10. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349(9068):1793-1796.
11. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
12. Petersen RC, Parisi J, Dickson D, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63(5):665-672.
13. De Leon MJ, George A, Golomb J, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging. 1997;18(1):1-11.
14. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992.
15. Visser PJ, Kester A, Jolles J, et al. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006;67(7):1201-1207.
16. Ravaglia G, Forti P, Maioli F, et al. Screening for mild cognitive impairment in elderly ambulatory patients with cognitive complaints. Aging Clin Exp Res. 2005;17(5):374-379.
17. Folstein MF, Folstein S, McHugh P. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
18. Brodaty H, Moore C. The Clock Drawing Test for dementia of the Alzheimer's type: a comparison of three scoring methods in a memory disorders clinic. Int J Geriatr Psychiatry. 1997;12(6):619-627.
19. Trenkle DL, Shankle WR, Azen SP. Detecting cognitive impairment in primary care: performance assessment of three screening instruments. J Alzheimers Dis. 2007;11(3):323-335.
20. Straus S, Richardson W, Glasziou P, et al. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd ed. Edinburgh, Scotland: Churchill Livingstone; 2005.
21. Nelson AP, O'Connor MG. Mild cognitive impairment: a neuropsychological perspective. CNS Spectr. 2008;13(1):56-64.
22. Petersen RC. The current status of mild cognitive impairment: what do we tell our patients? Nat Clin Pract Neurol. 2007;3(2):60-61.
23. Hartman-Stein P, Potkanowicz E. Behavioral determinants of healthy aging: good news for the baby boomer generation. Online J Issues Nurs. 2003;8(2):6.
24. Solfrizzi V, Capurso C, D'Introno A, et al. Lifestyle-related factors in predementia and dementia syndromes. Expert Rev Neurother. 2008;8(1):133-158.
25. Brayne C, Fox C, Boustani M. Dementia screening in primary care: is it time? JAMA. 2007;298(20):2409-2411.
26. Ashford J, Borson S. Primary care screening for dementia and mild cognitive impairment [letter]. JAMA. 2008;299:132.
27. Rafii M, Galasko D. Primary care screening for dementia and mild cognitive impairment [letter]. JAMA. 2008;299:132.
28. Larson EB. An 80-year-old man with memory loss. JAMA. 2000;283(8):1046-1053.
29. Tuokko H, Tallman K, Beattie BL, et al. An examination of driving records in a dementia clinic. J Gerontol B Psychol Sci Soc Sci. 1995;50(3):S173-S181.
30. Chodosh J, Petitti D, Elliott M, et al. Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc. 2004;52(7):1051-1059.
31. Boustani M, Peterson B, Hanson L, et al. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138(11):927-937.
32. Qizilbash N, Schneider LS, Chui H, et al. Evidence-Based Dementia Practice. eds Oxford, UK: Blackwell Science Ltd; 2002:357-852.
33. Brodaty H, Low L-F, Gibson L, et al. What is the best dementia screening instrument for general practitioners to use? Am J Geriatr Psychiatry. 2006;14(5):391-400.
34. Diniz B, Yassuda M, Nunes P, et al. Mini-Mental State Examination performance in mild cognitive impairment subtypes. Int Psychogeriatr. 2007;(1):1-10.
35. Nasreddine ZS, Phillips N, Bédirian V, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
36. Knopman DS, DeKosky S, Cummings J, et al. Practice parameter: diagnosis of dementia (an evidence-based review); reprt of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.
37. Ries ML, Carlsson C, Rowley H, et al. Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. J Am Geriatr Soc. 2008;56(5):920-934.
38. Staekenborg SS, van der Flier W, van Straaten E, et al. Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke. 2008;39(2):317-322.
39. Aggarwal NT, Bienias J, Bennett DA, et al. The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology. 2006;26(3):140-146.
40. Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology. 2004;63(10):1898-1901.
41. Reitz C, Tang MT, Luchsinger J, et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61(5):705-714.
42. Pappolla MA, Bryant-Thomas T, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61(2):199-205.
43. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand. 2006;114(2)(suppl 185):71-77.
44. Sparks D, Connor D, Sabbagh M, et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand. 2006;114(suppl 185):3-7.
45. Alberts MJ, Ovbiagele B. Current strategies for ischemic stroke prevention: role of multimodal combination therapies. J Neurol. 2007;254(10):1414-1426.
46. Cukierman T, Gerstein H, Williamson J. Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460-2469.
47. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;(2):CD004034.
48. Logroscino G, Kang J, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ. 2004;328(7439):548.
49. Hentschel F, Damian M, Krumm B, et al. White matter lesions-age-adjusted values for cognitively healthy and demented subjects. Acta Neurol Scand. 2007;115(3):174-180.
50. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683-1689.
51. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288(12):1475-1483.
52. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry. 2001;35(6):776-781.
53. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol. 2004;61(8):1290-1293.
54. Mulsant BH, Pollock B, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60(2):198-203.
55. Schmitt JA, Kruizinga M, Riedel W. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol. 2001;15(3):173-179.
56. Ellison J, Verma S, Sivrioglu Y. Pharmacotherapy of late life depression: review and recommendations. In: Ellison J, Verma S, eds. Depression in Later Life. New York, NY: Marcel Dekker Inc; 2003:193-224.
57. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? a double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007;27(1):67-70.
58. Dunner DL, Zisook S, Billow A, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59(7):366-373.
59. Scarmeas N, Stern Y, Tang M, et al. Mediterranean diet and risk for Alzheimer disease. Arch Neurol. 2006;63(12):1709-1717.
60. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402- 1408.
61. Durga J, van Boxtel M, Schouten E, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomized, double blind, controlled trial. Lancet. 2007;369(9557):208- 216.
62. McMahon JA, Green T, Skeaff M, et al. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354(26):2764-2772.
63. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: review of their intracellular targets. Eur J Pharmacol. 2006;545(1):51-64.
64. Petersen R, Thomas R, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
65. Williams P, Rands G, Orrel M, et al. Aspirin for vascular dementia. Cochrane Database Syst Rev. 2000;4(4):CD001296.
66. Thal L, Ferris S, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204-1215.
67. Resnick S, Maki P, Rapp S, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91(5):1802-1810.
68. Larson E, Wang L, Bowen J, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006;144(2):73-81.
69. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease. JAMA. 2008;300 (9):1027-1037.
70. Feldman H, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501-512.
71. Sobow T, Kloszewska I. Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. Neurol Neurochir Pol. 2007;41(1):13-21.
72. Important prescribing information. FDA Web site. http://www.fda.gov/ medwatch/SAFETY/2005/reminylDDLmarch.pdf. Posted March 31, 2005. Accessed June 7, 2007.
73. Ferris S, Schneider L, Farmer M, et al. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry. 2007;22(5):448-455.
74. Pharmaceutical Research and Manufacturers of America. New medicines database. http://newmeds.phrma.org/results.php?drug=&indication= 414&company=&status=. Accessed January 12, 2008.
75. Chistensen D. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry. 2007;9(1):32-41.
76. Alexopoulos G, Raue P, Arean P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiatry. 2003;11(1):46-52.
77. Belleville S. Cognitive training for persons with mild cognitive impairment. Int Psychogeriatr. 2008;20(1):57-66.
78. Kurz A, Pohl C, Ramsenthaler M, et al. Cognitive rehabilitation in patients with mild cognitive impairment [published online July 17, 2008]. Int J Geriatr Psychiatry.
79. Ball K, Roenker D, Wadley V, et al. Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc. 2006;54(1):77-84.
80. Molnar F, Patel A, Marshall S, et al. Systematic review of the optimal frequency of follow-up in persons with mild demnetia who continue to drive. Alzheimer Dis Assoc Disord. 2006;20(4):295-297.
81. Friedland R, Koss E, Kumar A, et al. Motor vehicle crashes in dementia of the Alzheimer type. Ann Neurol. 1988;24(6):782-786.
82. Physician's Guide to Assessing and Counseling Older Drivers. Chicago, IL: American Medical Association; 2003.
83. Okonkwo O, Wadley V, Griffith H, et al. Cognitive correlates of financial abilities in mild cognitive impairment. J Am Geriatr Soc. 2006;54(11):1745-1750.
84. Peters O, Froelich L, Heuser I, et al. Controlled discontinuation of antidementive treatment in MCI causes moderate cognitive deterioration. Alzheimers Dement. 2006;2(3S):S509.
85. Helmer C, Damon D, Letenneur L, et al. Marital status and risk of Alzheimer's disease: a French population-based cohort study. Neurology. 1999;53(9):1953-1958.
86. Beard C, Kokmen E, Offord K, et al. Lack of association between Alzheimer's disease and education, occupation, marital status, or living arrangement. Neurology. 1992;42(11):2063-2068.
87. Räihä I, Kaprio J, Koskenvuo M, et al. Environmental differences in twin pairs discordant for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1998;65(5):785-787.
88. Mittelman M. Psychosocial intervention for dementia caregivers: what can it accomplish? Int Psychogeriatr. 2003;15(suppl 1):247-249.
89. Silverman D, Small G, Chang C, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120-2127.